The siRNAs targeting Homo sapiens lnc‐Ip53 (GeneBank accession No. NR_037177.1), p53 (NM_000546.5), p300 (NM_001429.3), CBP (NM_004380.2), MOZ (NM_006766.4), and HDAC1 (NM_004964.2) transcripts are designated as silnc‐Ip53, sip53, sip300, siCBP, siMOZ, and siHDAC1, respectively, and were purchased from GenePharma (Shanghai, China). The negative control (NC) RNA duplex for siRNA is nonhomologous to any human genome sequences. The sequences of oligos are listed in Table S2, Supporting Information.
Si p53
Manufactured by GenePharma
Sourced in China
Si-p53 is a laboratory equipment product designed for gene manipulation and analysis. It functions as a small interfering RNA (siRNA) that targets the p53 gene, which is involved in cellular processes such as cell cycle regulation and apoptosis. The core function of Si-p53 is to temporarily suppress the expression of the p53 gene, allowing for the study of its role in various biological systems.
Automatically generated - may contain errors
Lab products found in correlation
Si nc, by GenePharma (2 mentions)
Sihdac1, by GenePharma (1 mentions)
Sip300, by GenePharma (1 mentions)
Mir 149 3p mimic, by GenePharma (1 mentions)
Lipofectamine 3000, by Thermo Fisher Scientific (1 mentions)
Sh con, by Genechem (1 mentions)
Lipofectamine 2000, by Thermo Fisher Scientific (1 mentions)
Fugene 6, by Promega (1 mentions)
Scrambled sirna, by GenePharma (1 mentions)
Si con, by GenePharma (1 mentions)
Pcdna3.1 vector, by GenePharma (1 mentions)
Pifithrin α, by GenePharma (1 mentions)
6 protocols using si p53
1
siRNA Targeting Regulators of p53
2
Transfection of miR-149-3p and p53 modulators
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
miR-149-3p mimics, inhibitors, siPDK2, sip53, and their corresponding NC oligonucleotide sequences were synthesized by GenePharma (Shanghai, China). Flag-p53 plasmid was kindly provided by Dr. Lu (Hua Lu, Fudan University, Shanghai, China). Transfection was performed with Lipofectamine 3000 (Invitrogen, CA, USA) at a final concentration of 50 nmol/L (mimics and siRNAs) or 100 nmol/L (inhibitors). Cells were harvested for assays 24 or 48 h after transfection. The siRNA, mimic, and inhibitor sequences are shown in Supplementary Table 2 .
3
Silencing p53 and DR5 in LX-2 cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Small-interfering RNA (siRNA) against p53 and scrambled siRNA were synthesized by GenePharma (China), and their sequences were as follows: the p53-specific siRNA (si-p53) 5′-GACTCCAGTGGTAATCTACTT-3′ and scrambled control siRNA (si-con): 5′-UUCUCCGAACGUGUCACGUTT-3′ [16] (link). To silence the expression of the p53 gene, LX-2 cells were transfected with si-p53 using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's instructions. After transfected for 30 h, the cells were treated with or without the SEA for another 18 h and then harvested for western blot and quantitative real-time polymerase chain reaction (qRT-PCR) assays.
To silence DR5 expression, we transfected shRNA-control (sh-con, Genechem, China) or shRNA-DR5 (sh-DR5, Genechem, China) in LX-2 cells using FuGENE 6 (Promega, USA) according to the manufacturer's instructions. After transfection for 30 h, the cells were treated with or without the SEA for another 18 h and then harvested for western blot and qRT-PCR assays.
To silence DR5 expression, we transfected shRNA-control (sh-con, Genechem, China) or shRNA-DR5 (sh-DR5, Genechem, China) in LX-2 cells using FuGENE 6 (Promega, USA) according to the manufacturer's instructions. After transfection for 30 h, the cells were treated with or without the SEA for another 18 h and then harvested for western blot and qRT-PCR assays.
4
Regulation of p53 and p65 in Nucleus Pulposus Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Small interfering RNA (si)-p53, si-negative control (NC), si-p65, p53 inhibitor (Pifithrin-α; 20 µM), pcDNA 3.1 vector, pcDNA 3.1-p53 and pcDNA 3.1-p65 were purchased from Shanghai GenePharma Co., Ltd. The siRNA sequences are presented in Table I . The cells were treated with Pifithrin-α for 24 h at 37°C.
Nucleus pulposus cells were cultured (5×105 cells/well) in 6-well plates for 24 h to 60–80% confluence. Subsequently, cells were transfected with 50 nM vector or 75 pmol siRNA using Lipofectamine® 2000 transfection reagent (cat. no. 11668019; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Following incubation for 6 h at 37°C, the medium was replaced with DMEM supplemented with 10% FBS and cells were incubated for a further 24 h at 37°C. Subsequently, p53 and p65 expression levels were detected by western blotting and cytokine expression levels were measured by reverse transcription-quantitative PCR (RT-qPCR).
Nucleus pulposus cells were cultured (5×105 cells/well) in 6-well plates for 24 h to 60–80% confluence. Subsequently, cells were transfected with 50 nM vector or 75 pmol siRNA using Lipofectamine® 2000 transfection reagent (cat. no. 11668019; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Following incubation for 6 h at 37°C, the medium was replaced with DMEM supplemented with 10% FBS and cells were incubated for a further 24 h at 37°C. Subsequently, p53 and p65 expression levels were detected by western blotting and cytokine expression levels were measured by reverse transcription-quantitative PCR (RT-qPCR).
5
Silencing p53 Enhances Plumbagin Effects
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For transfection, cells were assigned into the following groups: si-NC, si-NC + plumbagin, si-p53 and si-p53 + plumbagin. To examine the mechanism of action of plumbagin, p53 was silenced before plumbagin treatment (15 μmol/L). si-p53 and corresponding si-NC were synthesized by GenePharma Co., Ltd. (China). To prepare a transfection complex, the procedure involved combining 25 μL of reagent A with 25 μL of reagent B and mixing them thoroughly by aspirating the mixture 10 times using a pipette, followed by a 15-min incubation period. After that, cells were transfected with 50 μL of the resulting transfection complex.
6
Silencing UBD and p53 in HepG2 Cells
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Short interfering RNA (siRNA) against UBD siRNA (si-UBD) or p53 (si-p53) and control siRNA (si-NC) with nonspecific targeting sequences were synthesized by Gene Pharma Co. (Shanghai, China). The sequences were as follows: si-UBD-1 (5′-GCAUCAGAAAGGGCAACUUAC-3′); si-UBD-2 (5′-GCUGGGCUCCAAGAUCUUA-3′); p53 siRNA-1 (5′-GAAAUGUUCUUGCAGUUAAGG-3′); p53 siRNA-2 (5′-GCAGUUAAGGGUUAGUUUACA-3′); NC siRNA (5′-UUCUCCGAACGUGUCACGU-3′). HepG2 cells were grown to 40% confluence in 6-well plates and transiently transfected with 100 nM siRNAs using Lipofectamine 2000. The cells were analyzed either at 24 h post-transfection for in vitro migration assay or at 36 h post-transfection for Western blot.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!